4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$3.11B
Enterprise ValueAU$2.97B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding590,570,500
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.47Price Target Upside-23.52% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)AU$8.53M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Imaging Platform4DMedical’s XV imaging and XV Lung Ventilation Analysis platform represent proprietary, clinically focused software that creates functional lung maps. This technical differentiation supports durable clinical adoption, creates higher switching costs, and underpins recurring clinical integrations and revenue potential over months.
Conservative LeverageA relatively low debt-to-equity profile gives 4DMedical financial flexibility during continued commercial scaling. Lower leverage reduces refinancing and default risk, allowing management to prioritize clinical validation, go-to-market investment, or product development without immediate pressure to cut costs or raise dilutive capital.
Clinical Commercialization ChannelsDirect commercialisation via clinical and provider channels increases the likelihood of durable uptake: integration into clinical workflows builds long-term relationships, potential for recurring service or license revenues, and creates regulatory/clinical validation barriers that protect market position.
Bears Say
Revenue DeclineA year-over-year revenue decline signals weaker commercial traction and impairs scale economics. Without reversing top-line trends, the company faces tougher unit economics, reduced ability to absorb fixed R&D and commercialization costs, and a longer path to sustainable profitability over the next several quarters.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows constrain internal funding for commercialization and product development. Even with slight free cash flow growth, ongoing cash burn necessitates external financing or material margin improvement, creating execution and dilution risk in the medium term.
Sustained Losses & Negative ROEOngoing net losses, negative EBIT margins, and negative ROE indicate the business currently destroys shareholder capital. Unless the company materially improves margins or achieves significant revenue scale, continued losses will pressure balance sheet strength and require financing, challenging long-term viability.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$3.11B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 124 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 590,570,500 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$4.47 (-23.52% Downside)
AU$4.47 (-23.52% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 93%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth AU$9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.47
▼(-23.52% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---